Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Glofitamab is a T-cell–engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutchings, Martin, Morschhauser, Franck, Iacoboni, Gloria, Carlo-Stella, Carmelo, Offner, Fritz C., Sureda, Anna, Salles, Gilles, Martínez-Lopez, Joaquín, Crump, Michael, Thomas, Denise N., Morcos, Peter N., Ferlini, Cristiano, Bröske, Ann-Marie E., Belousov, Anton, Bacac, Marina, Dimier, Natalie, Carlile, David J., Lundberg, Linda, Perez-Callejo, David, Umaña, Pablo, Moore, Tom, Weisser, Martin, Dickinson, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210975/
https://www.ncbi.nlm.nih.gov/pubmed/33739857
http://dx.doi.org/10.1200/JCO.20.03175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210975/
https://www.ncbi.nlm.nih.gov/pubmed/33739857
http://dx.doi.org/10.1200/JCO.20.03175

Ejemplares similares